Thomas E. Keane, MD

Thomas E. Keane, MD

Medical University of South Carolina

Charleston, SC

Thomas E. Keane, MD, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a United States patent for sphingolipid derivatives and their use. Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urology, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.

Articles by Thomas E. Keane, MD

Timing of ADT with Chemotherapy in 2019

Thomas E. Keane, MD, reviews the data supporting and opposing the advancement of chemotherapy into the metastatic castration-sensitive prostate cancer (mCSPC) disease state. He then discusses a current trial introducing chemotherapy in patients prior to androgen deprivation therapy (ADT).

Read More

Timing of ADT and Chemotherapy

Thomas E. Keane, MD, discusses how the current prostate cancer treatment paradigm is evolving. He argues for moving androgen deprivation therapy (ADT) upfront in a patient’s treatment, but also acknowledges this approach could potentially hinder responsiveness to second-line therapies.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -